BSX Unveils New-Age Catheter - Analyst Blog
December 23 2011 - 9:45AM
Zacks
Boston Scientific
Corporation (BSX) has strengthened its Peripheral
Interventions (PI) business with the recent launch of Charger
percutaneous transluminal angioplasty (PTA) balloon catheter. The
device is meant for a wide range of peripheral angioplasty
procedures including post-stent dilatation.
This is the third new peripheral
balloon catheter launched in 2011. Earlier launches include Mustang
percutaneous transluminal angioplasty balloon (June 2011) and the
Coyote balloon catheter (September 2011). Both resulted in
increased market share for the company.
During the most recent quarter, PI
segment sales were $182 million, up 9% year over year (up 4% at
CER) despite a slowdown in US procedures that led to a 2.5% decline
in US sales ($77 million). Growth in PI stent systems was driven by
the Epic self-expanding nitinol stent system in certain
international markets and the Carotid Wallstent stent system in
Japan. The company expects to launch the Epic stent system in the
US in late 2012 or early 2013.
Under PI, management is also seeing
robust uptake in its interventional oncology franchise. Products
slated to be launched in 2012 are expected to drive the top line
further.
Boston Scientific has resorted to a
diversification through acquisition strategy. To this end the
company acquired S.I. Therapies and ReVascular Therapeutics in
February 2011. These acquisitions further expanded the PI portfolio
with a re-entry catheter and intraluminal chronic total occlusion
(CTO) crossing device, enabling endovascular treatment in cases
that typically cannot be treated with standard endovascular
devices. The launch of Offroad re-entry catheter system in certain
international markets is expected in early 2012 with a limited
release of the Truepath intraluminal CTO device in the US and
certain other international markets, pending regulatory
approval.
These are trying times for MedTech
companies when the core segments of stents and defibrillators are
struggling for growth due to pricing pressure and a loss of market
share. Boston Scientific is not alone and its peers
Medtronic (MDT) and St Jude
Medical (STJ) are also witnessing similar challenges. In
this scenario, the company is working on reviving its top line by
expanding its product portfolio, either through pipeline
development or strategic acquisitions.
We are currently Neutral on the
stock, in line with the short-term Zacks #3 Rank (Hold).
MEDTRONIC (MDT): Free Stock Analysis Report
ST JUDE MEDICAL (STJ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
SJM (NYSE:STJ)
Historical Stock Chart
From May 2024 to Jun 2024
SJM (NYSE:STJ)
Historical Stock Chart
From Jun 2023 to Jun 2024